









Markets
/
Stocks
/
nasdaq-bysi
/

Beyondspring Inc

BYSI

1.940USD

-0.010-0.51%

Market hours （ET）Quotes delayed by 15 min

78.23MMarket Cap

LossP/E TTM



Beyondspring Inc

1.940

-0.010-0.51%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Beyondspring Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Beyondspring Inc's Score

Industry at a Glance

Industry Ranking

211 / 407

Overall Ranking

417 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

Target Price

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Beyondspring Inc Highlights

StrengthsRisks

BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on developing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for the debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.

Undervalued

The company’s latest PE is -69.10, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 5.85M shares, decreasing 1.50% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 11.60K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.58.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 6.85, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

6.85

Change



Financials

9.20

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.44

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.84

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Beyondspring Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 6.15, which is lower than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -69.10, which is -98.62% below the recent high of -0.95 and -24.10% above the recent low of -85.75.

Score

Industry at a Glance

Previous score

6.15

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 211/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 7.23, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 2.37 and the support level at 1.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.34

Change

-0.11

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.022

Buy

RSI(14)

53.223

Neutral

STOCH(KDJ)(9,3,3)

41.667

Neutral

ATR(14)

0.192

High Vlolatility

CCI(14)

1.842

Neutral

Williams %R

62.500

Sell

TRIX(12,20)

0.457

Sell

StochRSI(14)

0.494

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.988

Sell

MA10

1.952

Sell

MA20

1.880

Buy

MA50

1.834

Buy

MA100

2.013

Sell

MA200

1.846

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Huang (Lan)

4.26M

Decheng Capital LLC

4.36M

-1.53%

Jia (Linqing)

1.78M

+0.00%

BlackRock Institutional Trust Company, N.A.

529.90K

+356.94%

The Vanguard Group, Inc.

Star Investors

523.70K

Geode Capital Management, L.L.C.

256.21K

+951.43%

BlackRock Financial Management, Inc.

90.54K

Fabbio (Patrick)

53.86K

+119.03%

Majeti (Jiangwen)

50.91K

Tanaka Capital Management, Inc.

26.30K

-10.78%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 2.68, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.53. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.